Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery
- 22 January 2013
- journal article
- review article
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 7 (1-2), 123-135
- https://doi.org/10.1002/prca.201200067
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder of motor neurons leading to death of the patients, mostly within 2–5 years after disease onset. The pathomechanism of motor neuron degeneration is only partially understood and therapeutic strategies based on mechanistic insights are largely ineffective. The discovery of reliable biomarkers of disease diagnosis and progression is the sine qua non of both the revelation of insights into the ALS pathomechanism and the assessment of treatment efficacies. Proteomic approaches are an important pillar in ALS biomarker discovery. Cerebrospinal fluid is the most promising body fluid for differential proteome analyses, followed by blood (serum, plasma), and even urine and saliva. The present study provides an overview about reported peptide/protein biomarker candidates that showed significantly altered levels in certain body fluids of ALS patients. These findings have to be discussed according to proposed pathomechanisms to identify modifiers of disease progression and to pave the way for the development of potential therapeutic strategies. Furthermore, limitations and advantages of proteomic approaches for ALS biomarker discovery in different body fluids and reliable validation of biomarker candidates have been addressed.Keywords
This publication has 102 references indexed in Scilit:
- Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosisNature, 2012
- Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALSNeuron, 2011
- A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTDNeuron, 2011
- Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementiaNature, 2011
- Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALSNeuron, 2010
- Galectin-3 Is a Candidate Biomarker for Amyotrophic Lateral Sclerosis: Discovery by a Proteomics ApproachJournal of Proteome Research, 2010
- Applying proteomics to the diagnosis and treatment of ALS and related diseasesMuscle & Nerve, 2009
- Biomarker discovery in neurodegenerative diseases: A proteomic approachNeurobiology of Disease, 2008
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisNature, 1993